Bromantane (Ladasten)

Bromantane (Ladasten) is a unique adamantane derivative and actoprotector developed in the 1980s at the Zakusov State Institute of Pharmacology in Russia, originally field-tested by the Soviet military in Afghanistan for heat stress and marching fatigue. Unlike traditional stimulants that work through receptor agonism or reuptake inhibition, bromantane enhances dopamine and serotonin synthesis by upregulating the gene expression of tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC) — the rate-limiting enzymes in catecholamine production. It also strengthens GABAergic signaling by reducing GABA transporter expression, producing anxiolytic effects without sedation. Approved in Russia in 1997 for the treatment of asthenic disorders (neurasthenia), it uniquely combines stimulant and anxiolytic properties without tolerance, dependence, or withdrawal. A landmark 728-patient clinical trial demonstrated a 76% response rate with only 3% side effects.

• Motivation and Drive Enhancement
• Anti-Fatigue / Anti-Asthenia
• Cognitive Clarity Under Stress

Unique dual stimulant-anxiolytic action, 42% oral bioavailability, no tolerance or dependence, 76% clinical response rate, sustained benefits up to 1 month post-discontinuation, enhanced physical performance under stress, immunostimulatory effects

Bromantane penetrates neuronal nuclei and promotes demethylation of CpG islands in TH and AADC gene promoter regions, exposing binding sites for transcription factors (CREB, AP2). This induces mRNA synthesis for dopamine and serotonin biosynthetic enzymes — TH mRNA reaches 220% in VTA within 1 hour, with 2-2.5x upregulation in hypothalamus by 1.5-2 hours. Additionally, bromantane reduces GABA transporter (GAT) expression, decreasing GABA reuptake and strengthening GABAergic signaling for anxiolytic effects without sedation. Sustained genomic upregulation over 7-14 days creates stable neurotransmitter enhancement fundamentally different from traditional stimulants.

Research protocols from published literature — not dosing recommendations.

• Selank — Synergistic: Both developed in Russia with complementary anxiolytic mechanisms — Selank via GABAergic modulation, bromantane via dopaminergic enhancement. May provide balanced cognitive and mood support.
• Semax — Synergistic: Complementary nootropic pathways — Semax enhances BDNF/NGF while bromantane upregulates dopamine synthesis enzymes. Combined cognitive and motivational enhancement.
• Omberacetam (Noopept) — Compatible: Different cognitive enhancement mechanisms — Omberacetam modulates glutamate receptors while bromantane enhances dopamine synthesis. Potentially complementary for motivation and memory.
• MAOIs — Avoid Combination: Theoretical risk: bromantane increases dopamine and serotonin synthesis while MAOIs block their breakdown, creating potential for dangerous neurotransmitter accumulation. No clinical cases documented, but mechanism warrants avoidance.
• SSRIs (Prozac, Zoloft, etc.) — Monitor Combination: Theoretical concern: bromantane's hepatic metabolism may affect SSRI levels through shared metabolic pathways. No direct interaction studies exist. Monitor for changes in antidepressant efficacy if combining.
• Stimulants (Adderall, Ritalin) — Use Caution: Overlapping dopaminergic effects through different mechanisms. Bromantane increases dopamine synthesis while stimulants increase dopamine release/block reuptake. Risk of excessive dopaminergic stimulation.
• Caffeine — Compatible: Different stimulant mechanisms — caffeine blocks adenosine while bromantane upregulates dopamine synthesis. Common combination in biohacking protocols at normal caffeine doses.
• L-Tyrosine — Compatible: Bromantane upregulates TH enzyme which converts L-tyrosine to L-DOPA. Providing adequate substrate (L-tyrosine) may support the enhanced enzymatic capacity.

Day 1-3: Subtle stimulation and mood lift within 1.5-2 hours of dosing. Mild increase in motivation and energy.. Week 1: Noticeable improvement in baseline energy, reduced mental fatigue, emerging anxiolytic effects.. Week 2-3: Full therapeutic effects as TH/AADC gene expression reaches peak upregulation. Sustained motivation without peaks/crashes.. Week 3-4: Maximal benefits — stable mood, physical endurance, cognitive clarity under stress, anxiety reduction.. Post-cycle: Benefits persist 2-4 weeks after discontinuation due to sustained enzyme expression changes.. Notable: No tolerance development — effects remain consistent throughout cycle without dose escalation..

Exceptionally safe profile: LD50 of 9000 mg/kg in rats (90-180x therapeutic dose equivalent). 728-patient trial showed only 3% side effects and 0.8% discontinuation rate. No tolerance, dependence, or withdrawal documented in clinical use. Not FDA/EMA approved — use under personal discretion with medical supervision. Avoid combining with MAOIs — theoretical risk of neurotransmitter accumulation based on mechanism (no clinical cases documented). Monitor if combining with SSRIs — theoretical concern for metabolic interactions through shared hepatic pathways. Highly lipophilic — accumulates in adipose tissue, meaning effects and metabolite detection persist longer than half-life suggests. Anticholinergic effects only observed at extreme supratherapeutic doses (>600mg/kg in animals) — not relevant at clinical doses.

Exceptionally safe profile: LD50 of 9000 mg/kg in rats (90-180x therapeutic dose equivalent). 728-patient trial showed only 3% side effects and 0.8% discontinuation rate. No tolerance, dependence, or withdrawal documented in clinical use. Not FDA/EMA approved — use under personal discretion with medical supervision. Avoid combining with MAOIs — theoretical risk of neurotransmitter accumulation based on mechanism (no clinical cases documented). Monitor if combining with SSRIs — theoretical concern for metabolic interactions through shared hepatic pathways. Highly lipophilic — accumulates in adipose tissue, meaning effects and metabolite detection persist longer than half-life suggests. Anticholinergic effects only observed at extreme supratherapeutic doses (>600mg/kg in animals) — not relevant at clinical doses.

Bromantane (Ladasten) should be stored at Room temperature, protect from moisture and light.